Health News Archive - June 04, 2006
By Ransdell Pierson NEW YORK (Reuters) - Pfizer Inc.'s kidney cancer drug Sutent will soon become the favored first-line treatment for advanced forms of the disease, based on its ability to prolong survival in a late-stage trial described on Sunday, researchers said.
ATLANTA (Reuters) - Adding the Sanofi-Aventis drug Taxotere to initial chemotherapy raised the odds of surviving advanced head and neck cancer by at least three years, U.S. researchers said on Sunday.
By Toni Clarke ATLANTA (Reuters) - Wyeth said on Sunday that interim results of a late-stage trial of its experimental kidney cancer drug significantly increased survival in patients compared to standard therapy.
FRANKFURT (Reuters) - German drugmaker Schering AG and U.S. biotech firm Genzyme Corp have seen good preliminary results in a study of the drug MabCampath to treat leukemia, Schering said in a statement.
By Deena Beasley LOS ANGELES (Reuters) - Amgen Inc. said on Sunday that early results from mid-stage trials of its experimental drug denosumab show that it works at least as well as current therapies to limit bone loss in patients with late-stage cancer.
ATLANTA (Reuters) - Celgene Inc. said on Sunday its cancer drug Thalomid improved survival by a significant amount in elderly patients with multiple myeloma, a form of blood cancer.
By Toni Clarke ATLANTA (Reuters) - For the first time in decades there are new treatments available for kidney cancer, and as more data emerges about their efficacy, the competition looks set to heat up.
By Lisa Richwine ATLANTA (Reuters) - Switching to Pfizer Inc.'s drug Aromasin after a few years on another breast cancer treatment cut some women's risk of dying from the disease by 17 percent in a study released on Saturday.
Please read in fourth paragraph ... "24 weeks from 12 weeks" ... instead of ...
By Toni Clarke ATLANTA (Reuters) - A kidney cancer drug made by Bayer AG and Onyx Pharmaceuticals Inc. showed promise in a small lung cancer trial, according to data released on Sunday, further fueling competition with a drug from Pfizer Inc.
- a study of the individuals in a group of people within a specific context and their relationships.
- In rhetoric, the description of any one's personal appearance.